Dr. Henrich is the co-inventor of USP6 mRNA technology and a co-founder of Merlin Biotech. He completed his Ph.D. in Pharmacology from the University of Pennsylvania in 2018 under the supervision of Dr. Margaret Chou where he authored the first publications describing the unique anti-tumor properties of USP6. He continued his research as a post-doctoral researcher in Dr. Chou’s lab to parlay his thesis into cancer therapeutic and has joined Merlin Biotech to spearhead the commercialization of USP6 and lead the discovery and development of additional novel cancer immunotherapies.
OTHER MANAGEMENT MEMBERS
